Sentynl gets UK MHRA’s approval for Nulibry to treat MoCD Type A
The approval was based on findings from three clinical studies that demonstrated Nulibry's safety and effectiveness in MoCD…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Apr 24
The approval was based on findings from three clinical studies that demonstrated Nulibry's safety and effectiveness in MoCD…
17 Apr 24
According to the results, Imfinzi along with chemotherapy decreased the mortality risk by 26% versus chemotherapy alone at…
17 Apr 24
P95, a leading global provider of clinical and epidemiology services focused on vaccines and infectious diseases, has opened…
17 Apr 24
Vaccine candidate provides broad coverage against the five most common groups of bacteria causing invasive meningococcal disease and…
17 Apr 24
CSafe, an active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, proudly announces the launch of…
17 Apr 24
On Apr. 11, 2024, VITAL HealthCare, one of the 5 core business divisions of the VITAL Group, marked a stunning…
17 Apr 24
The 89th edition of the China International Medical Equipment Fair (CMEF) witnessed an impressive turnout of over 200,000 attendees from more…
17 Apr 24
Insightec reaffirms its position at the forefront of the medical technology industry with improved functionality, safety features, and…
17 Apr 24
Approval enables regulated analysis services for cell and gene therapies. This important milestone for TATAA Biocenter provides customers…
17 Apr 24
Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development